ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

Forgot password
  • Home
  • Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

22 Apr 2020 4:02 PM | Daniel Hawley (Administrator)

Original Paper: International Journal of Antimicrobial Agents

Gautret P, Lagier JC, Parola P, et al. Int J Antimicrob Agents 2020:105949.

View Journal Club Review


Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
(331) 248-7888 • sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software